|
|
Kythera Biopharmaceuticals Announces Positive Results From Two Phase 2 Studies with ATX-101 Demonstrating Reduction of Submental Fat
The injected drug is similar to lipodissolve, which has been offered in medical spas and by physicians
LOS ANGELES, January 6, 2009 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA)
today announced that it has successfully completed two Phase 2 clinical studies
demonstrating the efficacy, safety, and tolerability of its lead product candidate, ATX-
101, for the reduction of submental (‘under-the-chin’) fat. The two Phase 2, randomized,
double-blind, placebo-controlled, dose-ranging studies enrolled a total of 157 patients
and were conducted across 10 centers in the United Kingdom, Canada, and Australia.
Multiple physician and patient endpoints were evaluated. In both studies, ATX-101 was safe and tolerable and demonstrated statistically
significant efficacy versus placebo. The demonstrated aesthetic correction was
clinically meaningful and was matched by improvements in patient reported outcomes. “We are very pleased with the results and the aesthetic correction patients achieved.
ATX-101 has the potential to be the first drug approved for the reduction of localized
facial fat and an important tool for physicians in achieving optimal aesthetic outcomes
for their patients,” said Patricia Walker, MD, PhD, KYTHERA’s Chief Medical Officer.
“We look forward to presenting expanded results from these studies in a future peer-reviewed
forum.” Study Designs
Study 0603 was a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging
study which, enrolled 85 patients at five centers in the United Kingdom, Canada, and
Australia. This study varied drug concentrations while fixing other dosing parameters.
The study endpoints included safety, tolerability, and the evaluation of efficacy as
measured by both global physician assessment of submental fat (on a validated
aesthetic scale), as well as patient reported outcomes. Study 0707 was a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging
study which, enrolled 72 patients at seven centers in the United Kingdom, Canada, and
Australia. Five of these seven centers were distinct from Study 0603. Study 0707
varied injection spacing and volume at a fixed drug concentration. The study endpoints
were identical to Study 0603. About ATX-101
ATX-101 is a first-in-class injectable product being studied for the reduction of small
volumes of fat. ATX-101 clinical research is focused on treating localized facial fat
deposits, including submental fat. KYTHERA has completed two international
randomized, double-blind, placebo-controlled, Phase 2 studies with ATX-101 in the
treatment of submental fat as well as a U.S. Phase 1 pharmacokinetic study. About Submental Fat (SMF)
Submental fat is a localized subcutaneous fat deposit located immediately beneath the
chin and jawline. In the rapidly growing market of minimally-invasive, non-surgical facial
rejuvenation, the reduction of facial fat deposits to restore and reshape the jawline
remains one of the largest unmet patient needs. According to a recent national, multicenter,
clinical evaluation of more than 220 BOTOX® and dermal filler patients, 73% of
patients had excessive submental fat. About KYTHERA Biopharmaceuticals
KYTHERA is a privately held biopharmaceutical company that applies the tools of
biotechnology to develop innovative prescription therapeutics for aesthetic medicine.
KYTHERA has active programs in adipolysis, dermal contouring and pigmentation
modulation. For more information about Kythera, please visit the company’s Web site at
www.kytherabiopharma.com
Related Topics: Injection Lipolysis | Lipodissolve | Kythera | Spot Fat Reduction
Related Articles:
Beauty Buzz: Aeshetic Trends for the Week Ending November 20, 2009 - Come See What the Buzz is About
The Week in Beauty Trends at AHB Brain Monitoring Could Have Saved Michael Jackson's Life - Dr. Barry Friedberg says brain monitoring of propofol could have saved Michael Jackson's life despite the other drugs in his body. Beauty Buzz: Aesthetic Trends for November 19, 2009 - If you thought today was good, just wait for tomorrow -- an exciting Thursday at AHB! Beauty Buzz: Aesthetic Trends for November 18, 2009 - What we gather around the water cooler for.... Beauty Buzz: Aesthetic Trends for November 17, 2009 - It's a beautiful Tuesday at AHB! Procyte Skin Care Cosmeceuticals - Procyte is a combination of cosmetics and medicine known as a cosmeceutical. They have an extensive line of products for moisturizing, and anti-aging treatments. Beauty Buzz: Aesthetic Trends for November 16, 2009 - All the Buzz you can handle! Beauty Buzz: The Week in Review, November 13, 2009 - Happy Friday the 13th! Read About Prevage Anti-Aging Cream - Prevage from Elizabeth Arden moisturizes skin to prevent skin aging. Beauty Buzz: Aesthetic Trends for November 12, 2009 - That's what we're talkin' about! Beauty Buzz: Aesthetic Trends for November 11, 2009 - The Veteran's Day Buzz! Beauty Buzz: Aesthetic Trends for November 10, 2009 - It's what's all a-Buzz at AHB... Beauty Buzz: The Week in Review, November 6, 2009 - It's been a great start to November here at AHB... Beauty Buzz: Aesthetic Trends for November 5, 2009 - What's hot at AHB today?? Jane Iredale Mineral Cosmetics - Coverage without Clogging - Jane Iredale mineral cosmetics is a full-service line of makeup designed to meet the needs of any woman.
|
Locate Lipodissolve Providers |
|
|
|
|
Consumers researching Lipodissolve also researched:
The Beauty Buzz... Latest Headlines
-
-
-
-
-
-
-
-
-
-
The HOT List -- Most Researched Procedures Today on American Health and Beauty
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Most Popular Articles on AHB
-
-
-
-
-
-
-
-
-
-
|